Schizoaffective Disorders Treatment Market

Global Schizoaffective Disorders Treatment Market Size (2024 to 2029)

The size of the global schizoaffective disorders treatment market is predicted to grow at a CAGR of 2.88% from 2024 to 2029 and is anticipated to be worth USD 8.77 billion by 2029 from USD 7.61 billion in 2024.

A schizoaffective disorder is a mental health disorder with symptoms such as mania, depression, and schizophrenia tendencies like hallucinations and delusional behavior. Schizoaffective disorder shares symptoms with schizophrenia and bipolar disorder, which can lead to misdiagnosis. According to the Diagnostic and statistical manual of mental Disorders (DMS – 5), 0.3% of the population suffers from a schizoaffective disease where a woman population is more than the men. The typical age for schizoaffective disorder is early adulthood, although it can occur anytime from adolescence through late life.

MARKET DRIVERS

The growing adoption of unenergetic lifestyles and rising incidence of chronic diseases are propelling the global schizoaffective disorders treatment market growth.

People with schizoaffective disorder generally respond to a combination of medications and psychotherapy, and this medicine to the patient depends on the symptoms of the disease. Other methods like psychotherapy, life skills training, hospitalization, and electroconvulsive therapy are for adults who do not respond to psychotherapy or medication. Only one drug that the US FDA approves and many more are in the pipeline stage, propelling the market growth. Ongoing research in the field of schizoaffective disorder is boosting market growth. In addition, the adoption of advanced technology is significantly influencing the market's demand. 

The increasing funding toward the schizoaffective drug market is expected to help the revenue along with the growing rates of mental disorders worldwide.

For instance, schizoaffective disorder (1/2%) affects about one in every 200 persons at some point in their lives. One of the most prevalent major mental diseases, along with schizophrenia, is schizoaffective disorder. Furthermore, in the post-COVID era, there has been a rapid increase in mental disorders stats, leading to more revenue for the market. For example, according to WHO, in 2018, 970 million individuals worldwide, or 1 in every eight persons, had a mental illness, including anxiety and depressive disorders. Now, around 19.86% of adults are experiencing a mental illness worldwide. Therefore, there is a need for more awareness and care regarding mental health supporting the market expansion. 

MARKET RESTRAINTS

Stringent rules and regulations by the government regarding public safety are slowly declining the market's growth rate. In addition, the diagnosis of schizoaffective disorder is less reliable and is limiting the demand of the market. 

Impact Of COVID-19 On the Global Schizoaffective Disorders Treatment Market

Covid-19 led to a severe economic crisis worldwide. The disruption of demand and supply chain led to losses for major industries. The healthcare industry, however, faced significant problems due to the large influx of COVID-19 patients and panic among healthcare professionals due to a lack of resources and workforce. Like several other markets, the schizoaffective market also faced significant losses due to the pandemic. All the other healthcare facilities, including mental (psychological) care, were shut down in view of lockdowns and population quarantining. The focus was shifted to covid treatment, even clinical research; therefore, the pharmaceutical companies struggled with providing proper research and support to innovations in the field. However, the pandemic led to increased mental problems like depression, promising more revenue for the market in the post-COVID-19 era. 

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Schizoaffective Disorders Treatment Market Analysis By Treatment

The antipsychotic segment is leading with the highest shares of the market. The growth is credited to advanced healthcare facilities and the availability of a well-structured regulatory framework.

The mood stabilizers and antidepressants segment is also expected to dominate the market revenue during the forecast period because common psychological treatments include a combination of these drugs to induce treatment in the patient. Due to multiple symptoms and the need to curb all the problems, these diseases are prescribed to critically ill schizoaffective patients. 

Global Schizoaffective Disorders Treatment Market Analysis By Cause of Disorder

The genetic factors segment is the leading segment of the treatment of schizoaffective disease over the analysis period. Factors like quick improvement in the healthcare industry and the growing healthcare industry propel the market's growth.

The environmental factors segment is also expected to show significant revenue during the forecast period due to the rising levels of stress and pressure among the younger generations and the extensive stereotypes of perfect success in society today. 

Global Schizoaffective Disorders Treatment Market Analysis By Type

The manic segment is considered to hold the largest market share of the schizoaffective disorders treatment market. The growth is due to advance technologies for medical tourism, fast access to the required procedures of the medical field, and lower cost for discretionary processes.

The depressive segment is also expected to show significant growth in the market due to rising cases of youth diagnosed with clinical depression and needing support and help from professionals. The mixed type also prevails as mental disorder diagnoses become more complex and integrated. 

REGIONAL ANALYSIS

North America was the largest regional segment for schizoaffective disorders treatment globally in 2023, while Europe and the Asia Pacific regions followed. The dominance of North America and Europe is due to the advanced healthcare infrastructures, strict government rules regarding the production and supply of medications, and the increasing research and development in the field. Additionally, the presence of key market players in countries like the U.S., Canada, the U.K., France, Germany, Italy, etc., is expected to promote market growth in the region. 

The Asia-Pacific region is expected to have the fastest growth rate during the forecast period, owing to increasing healthcare spending, rising disposable income, availability of advanced healthcare facilities, and rising awareness about available healthcare facilities. Additionally, the Asia-Pacific market is rising due to the growing preference toward medical tourism and first-class service in countries like China, India, Japan, South Korea, etc., for lower costs than developed regions. 

KEY PLAYERS IN THE GLOBAL SCHIZOAFFECTIVE DISORDERS TREATMENT MARKET

Some of the major players in the global schizoaffective disorders treatment market profiled in this report are Merz Pharma GmbH & Co. KGaA., Eli Lilly and Company, Elan Pharmaceuticals, Ciba Pharmaceuticals, Abbott Pharmaceuticals, AstraZeneca plc, and Janssen-Cilag Pty Limited.

RECENT HAPPENINGS IN THE MARKET

• In November 2022, Alkermes updated its forecast for its fiscal year 2022 results. In contrast to the average expectation of $0.20, the business announced earnings per share (EPS) guidance of $0.15 to $0.33 for the relevant period. In contrast to the average sales forecast of $1.10 billion, the business provided revenue guidance of $1.07 billion to $1.12 billion.
• In November 2022, Leerink SVB Comments on the earnings for FY2024 of Alkermes plc. In research published on Wednesday, November 2, SVB Leerink lowered their FY2024 earnings per share (EPS) projections for shares of Alkermes. The business will now report earnings of $0.45 per share for the year, down from their previous expectation of $0.57, according to SVB Leerink analyst M. Goodman. The current full-year average estimate for Alkermes' profits is ($0.34) per share.
• In January 2020, ANI Pharmaceutical Inc. announced the launch of the Paliperidone Extended-Release tablet, which includes antipsychotic drugs.
• In April 2020, Pear Therapeutics, Inc. announced the launching of a limited distribution of its Pear–004.
• In October 2019, Delpor Inc. was moved very near to run the phase 3 clinical trials for the sustained-release formulation of the antipsychotic risperidone, which can treat schizophrenia.

DETAILED SEGMENTATION OF THE GLOBAL SCHIZOAFFECTIVE DISORDERS TREATMENT MARKET INCLUDED IN THIS REPORT

This report on the global schizoaffective disorders treatment market report has been segmented and sub-segmented based on treatment, cause of disorder, type, and region.

By Treatment

• Antipsychotics       
  • Aripiprazole
  • Clozapine
  • Haloperidol
  • Risperidone
  • Olanzapine
  • Others
• Mood Stabilizers   
  • Divalproex
  • Lithium
  • Others
• Antidepressants   
  • Desvenlafaxine
  • Fluoxetine
  • Escitalopram
  • Others
• Anticonvulsants   
  • Valproate
  • Carbamazepine
  • Others
• Psychotherapy      
  • Group Therapy
  • Psychotherapy & Counselling
  • Others

By Cause of Disorder

• Genetic Factors   
• Chemical Factors  
• Environmental Factors       

By Type

• Manic Type             
• Depressive Type   
• Mixed Type            
• Schizoaffective Disorders 

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa